Midatech Pharma PLC Rule 2.9 Announcement

TIDMMTPH

RNS Number : 5489K

Midatech Pharma PLC

22 April 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

22 April 2020

Midatech Pharma PLC

("Midatech" or the "Company")

Rule 2.9 Announcement - Typo correction

The following amendment has been made to Midatech's 2.9 announcement that was released on the 20 April 2020 which had the incorrect International Securities Identification Number ("ISIN") for the Company's American Depositary Receipts ("ADRs"). The ISIN for these ADRs is US59564R3021.

The announcement should have read:

In accordance with Rule 2.9 of the Takeover Code, Midatech confirms that, as at the date of this announcement, it has 23,494,981 ordinary shares with par value GBP0.001 in issue ("Ordinary Shares") and admitted to trading on the AIM market of the London Stock Exchange with International Securities Identification Number GB00BKT14T00. The Company has an American Depositary Receipts facility ("ADRs", where each ADR represents 5 Ordinary Shares) with 998,655 ADRs currently outstanding, representing 4,993,275 Ordinary Shares. The ADRs are registered with the US Securities and Exchange Commission ("SEC") and are listed on The NASDAQ Capital Market with International Securities Identification Number US59564R3021.

For more information, please contact:

 
 
   Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: +44 (0)1235 888300 
 www.midatechpharma.com 
 
 Panmure Gordon (UK) Limited (Financial Adviser, Nominated Adviser 
  and Broker) 
 Freddy Crossley, Emma Earl (Corporate Finance) 
 James Stearns (Corporate Broking) 
 Tel: +44 (0)20 7886 2500 
 
  Noble Capital Markets, Inc. (M&A adviser) 
  Michel Gouy, Tel. +43 664 230 2910 
  Wolfgang Stoiber Tel. +1 978 697 9753 
  mgouy@noblelsp.com / wstoiber@noblelsp.com 
 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: +44 (0)20 3934 6630 
 Email: midatech@investor-focus.co.uk 
 
 Edison Group (US Investor Relations) 
  Joseph Green/ Laine Yonker 
  Tel: (646) 653-7030/ 7035 
  jgreen@edisongroup.com/ lyonker@edisongroup.com 
 
 
   Publication on website 
   A copy of this announcement will be made available (subject 
   to certain restrictions relating to persons resident in restricted 
   jurisdictions) on the Company's website at www.midatechpharma.com 
   in accordance with Rule 26.1 of the Code by no later than 12 
   noon (London time) on 21 April 2020. For the avoidance of doubt, 
   the content of the website referred to in this announcement 
   is not incorporated into and does not form part of this announcement. 
   Disclosure requirements of the Code 
   Under Rule 8.3(a) of the Code, any person who is interested 
   in 1% or more of any class of relevant securities of an offeree 
   company or of any securities exchange offeror (being any offeror 
   other than an offeror in respect of which it has been announced 
   that its offer is, or is likely to be, solely in cash) must 
   make an Opening Position Disclosure following the commencement 
   of the offer period and, if later, following the announcement 
   in which any securities exchange offeror is first identified. 
   An Opening Position Disclosure must contain details of the person's 
   interests and short positions in, and rights to subscribe for, 
   any relevant securities of each of (i) the offeree company and 
   (ii) any securities exchange offeror(s). An Opening Position 
   Disclosure by a person to whom Rule 8.3(a) applies must be made 
   by no later than 3.30 pm (London time) on the 10th business 
   day following the commencement of the offer period and, if appropriate, 
   by no later than 3.30 pm (London time) on the 10th business 
   day following the announcement in which any securities exchange 
   offeror is first identified. Relevant persons who deal in the 
   relevant securities of the offeree company or of a securities 
   exchange offeror prior to the deadline for making an Opening 
   Position Disclosure must instead make a Dealing Disclosure. 
   Under Rule 8.3(b) of the Code, any person who is, or becomes, 
   interested in 1% or more of any class of relevant securities 
   of the offeree company or of any securities exchange offeror 
   must make a Dealing Disclosure if the person deals in any relevant 
   securities of the offeree company or of any securities exchange 
   offeror. A Dealing Disclosure must contain details of the dealing 
   concerned and of the person's interests and short positions 
   in, and rights to subscribe for, any relevant securities of 
   each of (i) the offeree company and (ii) any securities exchange 
   offeror(s), save to the extent that these details have previously 
   been disclosed under Rule 8. A Dealing Disclosure by a person 
   to whom Rule 8.3(b) applies must be made by no later than 3.30 
   pm (London time) on the business day following the date of the 
   relevant dealing. 
   If two or more persons act together pursuant to an agreement 
   or understanding, whether formal or informal, to acquire or 
   control an interest in relevant securities of an offeree company 
   or a securities exchange offeror, they will be deemed to be 
   a single person for the purpose of Rule 8.3. 
   Opening Position Disclosures must also be made by the offeree 
   company and by any offeror and Dealing Disclosures must also 
   be made by the offeree company, by any offeror and by any persons 
   acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). 
   Details of the offeree and offeror companies in respect of whose 
   relevant securities Opening Position Disclosures and Dealing 
   Disclosures must be made can be found in the Disclosure Table 
   on the Takeover Panel's website at www.thetakeoverpanel.org.uk, 
   including details of the number of relevant securities in issue, 
   when the offer period commenced and when any offeror was first 
   identified. You should contact the Takeover Panel's Market Surveillance 
   Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether 
   you are required to make an Opening Position Disclosure or a 
   Dealing Disclosure. 
   Additional information 
   Panmure Gordon (UK) Limited ("Panmure") is authorised and regulated 
   by the Financial Conduct Authority in the United Kingdom. Panmure 
   is acting as financial adviser in relation to the Code exclusively 
   for M idatech and no one else in connection with the matters 
   set out in this announcement and will not regard any other person 
   as its client in relation to the matters set out in this announcement 
   and will not be responsible to anyone other than Midatech for 
   providing the protections afforded to clients of Panmure or 
   its affiliates, or for providing advice in relation to the contents 
   of this announcement or any other matter referred to herein. 
 Noble Capital Markets ("Noble") is a research-driven boutique 
  investment bank that has supported small & micro-cap companies 
  since 1984. As a FINRA and SEC licensed, broker-dealer Noble 
  provides institutional-quality equity research, merchant and 
  investment banking, wealth management, and order execution services. 
  Noble Life Science Partners, a division of Noble Capital Markets, 
  Inc. combines industry and scientific knowledge to provide our 
  clients with value-added research, advisory, licensing, M&A, 
  and investment and merchant banking services. The Scientific 
  Advisory Board (SAB) was formed for the overall objective of 
  being instrumental and impactful in the growth and expansion 
  of platform through highly focused, in-depth, and substantive 
  advice with regards to new discoveries, technologies, products, 
  services, new developments/trends in the Medical/Biotechnology/Pharmaceutical 
  Industry worldwide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RTTPPUWCCUPUGCP

(END) Dow Jones Newswires

April 22, 2020 10:51 ET (14:51 GMT)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Jun 2024 to Jul 2024